# Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

> **NCT01752920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 119 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Derazantinib low dose range
- **DRUG:** Derazantinib middle dose range
- **DRUG:** Derazantinib high dose range
- **DRUG:** Derazantinib at recommended phase 2 dose (RP2D)

## Key facts

- **NCT ID:** NCT01752920
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-10
- **Primary completion:** 2018-08-28
- **Final completion:** 2018-08-28
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752920, "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01752920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*